The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and development of new CAR-T cell ...

Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

Scientists discovered that inhibiting the enzyme STK17B forces multiple myeloma cells into iron-driven death and makes ...

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

The multiple myeloma CAR-T market is growing due to the strong clinical success of BCMS-targeted therapies and rising cases of relapsed or refractory patients, reports Towards Healthcare a sister firm ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies ...

Although multiple myeloma is often considered incurable, the development of highly effective new therapies is creating a real possibility of a cure for some patients. Current 4-drug upfront regimens, ...

Intensive cytotoxic bridging therapy is linked to delayed recovery after CAR T-cell therapy for multiple myeloma.

The Royal Marsden Private Care Becomes The First In The UK To Treat Multiple Myeloma Patients With CAR-T Cell Therapy. <li ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...